CARDINAL HEALTH, INC. |
Market Closed -
Other stock markets
|
Pre-market 09:28:30 am | |||
| 103 USD | +0.79% |
|
102.9 | -0.05% |
| May. 02 | Leerink Partners Adjusts Cardinal Health Price Target to $120 From $118 | MT |
| May. 02 | Transcript : Cardinal Health, Inc., Q3 2024 Earnings Call, May 02, 2024 |
Financials (USD)
| Sales 2024 * | 226B | Sales 2025 * | 227B | Capitalization | 25.05B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.2B | Net income 2025 * | - | EV / Sales 2024 * | 0.11 x |
| Net cash position 2024 * | 544M | Net cash position 2025 * | 1.62B | EV / Sales 2025 * | 0.1 x |
| P/E ratio 2024 * |
18.4
x | P/E ratio 2025 * |
14.8
x | Employees | 47,520 |
| Yield 2024 * |
1.99% | Yield 2025 * |
2% | Free-Float | 74.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cardinal Health, Inc.
More recommendations
More press releases
| 1 day | +0.79% | ||
| 1 week | -0.80% | ||
| Current month | -0.06% | ||
| 1 month | -7.43% | ||
| 3 months | -0.46% | ||
| 6 months | +9.81% | ||
| Current year | +2.16% |
1 week
100.00
106.68
1 month
100.00111.95
Current year
100.00116.04
1 year
77.56116.04
3 years
45.85116.04
5 years
39.05116.04
10 years
39.05116.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jason Hollar
CEO | Chief Executive Officer | 51 | 20-04-26 |
Aaron Alt
DFI | Director of Finance/CFO | 53 | 23-02-09 |
Michelle Greene
CTO | Chief Tech/Sci/R&D Officer | 54 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 22-09-05 | |
| Director/Board Member | 71 | 13-09-11 | |
Gregory Kenny
CHM | Chairman | 71 | 06-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 103 | +0.79% | 3,684,813 |
| 24-05-01 | 102.2 | -0.84% | 2,858,908 |
| 24-04-30 | 103 | +0.13% | 2,456,082 |
| 24-04-29 | 102.9 | -0.29% | 1,690,855 |
| 24-04-26 | 103.2 | -0.58% | 1,399,916 |
Delayed Quote Nyse, May 02, 2024 at 04:00 pm EDT
More quotes
Cardinal Health, Inc. is specialized in the distribution of products and health services to pharmacies, hospitals and medical practices. Net sales break down by activity as follows:
- distribution of pharmaceutical products (92.7%);
- distribution of medical, surgical and laboratory products (7.3%). The group also develops a manufacturing of medical and surgical products activity (masks, overalls, gloves, diagnostic products, products of aspiration and collection of liquids, radiology intervention, respiratory assistance, etc.).
The United States accounts for 97.7% of net sales.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
103
USD
Average target price
112.9
USD
Spread / Average Target
+9.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.16% | 25.05B | |
| +14.53% | 69.68B | |
| +7.11% | 8.21B | |
| -20.55% | 7.96B | |
| -4.06% | 7.75B | |
| +2.20% | 4.64B | |
| +17.12% | 4.32B | |
| -1.24% | 4.09B | |
| -3.30% | 3.82B | |
| +21.42% | 3.62B |
- Stock Market
- Equities
- CAH Stock
